Navigation Links
Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
Date:5/11/2012

NANJING, China, May 11, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the annual general meeting of shareholders (the "Meeting") will be held on Friday, May 25, 2012 at 10 a.m. Beijing time. The meeting will be held at No.699-18, Xuanwu Avenue, Xuanwu District, Nanjing, the People's Republic of China.

The meeting's main purposes are:

  1. To receive a report on the Company's operations.
  2. To transact any other business properly brought before the Meeting.

All shareholders of record at the close of business on May 11, 2012 will be entitled to attend and vote at the Meeting, and at any adjournment or postponement thereof, or to appoint a proxy to attend and vote in his/her place. The proxy need not be a shareholder of the Company.

This notice and other information with regards to the Meeting are available on the investor relations section of the Company's website: www.simcere.com.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group ("Simcere") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com. Investor and Media Contacts:  Email: ir@simcere.com

 In Nanjing:In the United States:Yehong Zhang

Cindy ZhengPresident

Brunswick Group LLCSimcere Pharmaceutical GroupTel: 1-212-333-3810Tel: 86-25-8556-6666 ext 8811In Beijing:In Hong Kong:Yue Yu

Joseph Lo Chi-LunBrunswick Group

Brunswick GroupTel: 86-10-5960-8600

Tel: 852-3512-5000 


'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
8. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
9. Simceres Diosmectite API Passes EU-GMP Inspection
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
11. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
(Date:7/13/2017)...  Centurion Medical Products, a leader in medical product innovation and ... removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a ... pain while preventing unneeded emergency department admission due to severe fecal ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson ... Witness , was awarded a $300,000 grant from The Pew Center for Arts ... with ambiguity and the recognition of one’s own limits among health professions students. ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... $5,000 grant from the C. R. Bard Foundation, Inc. to support ... Hills , a service available through the nonprofit home care agency. Using evidence-based ...
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
(Date:7/20/2017)... ATLANTA, Ga. (PRWEB) , ... July 20, 2017 , ... ... and equal access to medicine for everyone affected by diabetes, is teaming up with ... the five-day global event kicks off on July 24th. , “Team Type 1’s ...
Breaking Medicine News(10 mins):